KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study.

Se Hoon Park, Yen-Hwa Chang, Jae Lyun Lee, Toni K Choueiri, Go Kimura, Jinsoo Chung, Naoya Masumori, Kazuo Nishimura, Minoru Kato, Haruaki Kato, Kazuyuki Numakura, Chao-Hsiang Chang, Satoshi Anai, Hiroyuki Tsunemori, Chung-Hsin Chen, Jianxin Lin, Aymen Elfiky, Joseph E Burgents, Hiroshi Kitamura

Cancer Res Treat 58(2) 613-621

PMID40575946
PMCIDPMC13093030
DOI10.4143/crt.2025.365
发表日期2025-06-27
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

PURPOSE: Adjuvant pembrolizumab improved disease-free survival (DFS) and overall survival (OS) versus placebo in participants with renal cell carcinoma (RCC) at increased risk of recurrence after nephrectomy in the global phase 3 KEYNOTE-564 study. This post hoc subgroup analysis evaluated the efficacy and safety of adjuvant pembrolizumab in East Asian (Japan, South Korea, and Taiwan) participants enrolled in KEYNOTE-564. MATERIALS AND METHODS: Eligible participants were randomly assigned 1:1 to receive adjuvant pembrolizumab 200 mg or placebo intravenously every 3 weeks for ≤ 17 cycles. The primary endpoint was DFS by investigator assessment. OS was a key secondary endpoint. Safety was a secondary endpoint. RESULTS: The East Asian subgroup included 126 participants (pembrolizumab, n=58; placebo, n=68). Median follow-up was 62.1 months (range, 49.6 to 73.0 months). Hazard ratio for DFS with pembrolizumab versus placebo was 0.70 (95% confidence interval 0.41 to 1.20). Median DFS was not reached with pembrolizumab versus 58.8 months with placebo; estimated 48-month rate was 61.3% versus 51.2%. Hazard ratio for OS was 0.47 (95% confidence interval, 0.15 to 1.49). Median OS was not reached with pembrolizumab and placebo; estimated 48-month rate was 94.8% versus 91.2%. Treatment-related adverse events occurred in 70.7% of participants (29.3% grade 3 or 4) receiving pembrolizumab and 36.8% of participants (0.0% grade 3 or 4) receiving placebo. No pembrolizumab-related deaths occurred. CONCLUSION: In the KEYNOTE-564 East Asian subgroup, adjuvant pembrolizumab provided DFS and OS benefits versus placebo and had a safety profile consistent with the global results. These results further support pembrolizumab as adjuvant treatment for East Asian patients with RCC at increased risk of recurrence after nephrectomy.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2.

Fig. 2. Kaplan-Meier estimates of disease-free survival in the East Asian intention-to-treat population. CI, confidence interval; HR, hazard ratio; NR, not reached.

Disease-free_survival_in_the_East_Asian_intention-to-treat_population

disease-free survival

Fig. 2. · Panel Disease-free_survival_in_the_East_Asian_intention-to-treat_population

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Disease-free_survival_in_the_East_Asian_intention-to-treat_population 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Fig. 3.

Fig. 3. Kaplan-Meier estimates of overall survival in the East Asian intention-to-treat population. CI, confidence interval; HR, hazard ratio; NR, not reached.

Overall_survival

overall survival

Fig. 3. · Panel Overall_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Overall_survival 是同一 Fig. 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Fig. 1. Participant disposition in the East Asian intention-to-treat population.
非 KM Figure